Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557108 | 0.88 | MTNR1A (0.36) | MTNR1AMTNR1BHTR2CALDH1A1HPGD | |
| SCHEMBL555862 | 0.81 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2CALDH1A1HPGD | |
| SCHEMBL534788 | 0.80 | CYP3A4 (0.33) | ALDH1A1HPGDKDM4ELMNACYP3A4 | |
| SCHEMBL27975504 | 0.67 | CYSLTR2 (0.42) | MTNR1AMTNR1B | |
| SCHEMBL27495954 | 0.64 | CYSLTR2 (0.50) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL533834 | 0.62 | MTNR1A (0.59) | MTNR1AMTNR1BHTR2CLMNACYP2C19 | |
| SCHEMBL27893498 | 0.62 | MTNR1A (0.48) | MTNR1AMTNR1BHTR2CPOLBCYP2C9 | |
| SCHEMBL8594336 | 0.60 | MTNR1A (0.61) | MTNR1AMTNR1BL3MBTL1POLBLMNA | |
| SCHEMBL29709911 | 0.58 | GABRA1 (0.43) | HTR2CHPGDL3MBTL1POLBLMNA | |
| SCHEMBL14361142 | 0.58 | MTNR1A (0.67) | MTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MTNR1A 2293/4885MTNR1B 1285/4885HTR2C 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.